171 – 180 of 397
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Changes in prandial glucagon levels after 2 years treatment with vildagliptin or glimepiride
(2009) 45th Annual Meeting of the European-Association-for-the-Study-of-Diabetes In Diabetologia 52(Suppl 1). p.798-798
- Contribution to journal › Published meeting abstract
-
Mark
beta-Cell research - A decade of rapid growth
- Contribution to journal › Article
-
Mark
GIP and GLP-1 normalize glucose tolerance by normalizing islet adaptation to insulin resistance without increasing glucose effectiveness in high-fat fed mice
(2009) 45th Annual Meeting of the European-Association-for-the-Study-of-Diabetes In Diabetologia 52(Suppl 1). p.197-197
- Contribution to journal › Published meeting abstract
-
Mark
Modulation of Fasted and Postprandial Plasma Lipids in Healthy Volunteers by a Dietary Mixture of Omega-3 Fatty Acids and Conjugated Linoleic Acid
- Contribution to journal › Article
-
Mark
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
- Contribution to journal › Article
-
Mark
Differential Islet and Incretin Hormone Responses in Morning vs. Afternoon after Standardized Meal in Healthy Men.
- Contribution to journal › Article
-
Mark
Reappraisal of the intravenous glucose tolerance index for a simple assessment of insulin sensitivity in mice
(2009) In American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 296(5). p.1316-1324
- Contribution to journal › Article
-
Mark
beta- and alpha-Cell Dysfunction in Subjects Developing Impaired Glucose Tolerance Outcome of a 12-Year Prospective Study in Postmenopausal Caucasian Women
- Contribution to journal › Article
-
Mark
Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study
- Contribution to journal › Article
-
Mark
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events
- Contribution to journal › Article